Valproic Acid
Research News and Information

Saturday, November 21, 2009

Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation.

16 Sep 2009 Neuroprotective properties of the mood stabilizer valproic acid (VPA) are implicated in its therapeutic efficacy. Heat-shock protein 70 (HSP70) is a molecular chaperone, neuroprotective and anti-inflammatory agent. This study aimed to investigate ... Read more...

An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential.

30 Aug 2009 OBJECTIVES: Progress toward understanding the neurobiological and genetic underpinnings of bipolar disorder has been limited by the scarcity of potential biological markers that predict its occurrence. A measure of the integrity of brain inhibitory ... Read more...

Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells.

30 Aug 2009 Camptothecin derivatives have been widely used for chemotherapy in patients with various cancers, but intrinsic and acquired drug resistance is major drawback to be overcome. In the present study, we demonstrated that simultaneous treatment with ... Read more...

Latest indexed articles for 'Valproic Acid'

These are the very latest articles for this heading:

• Combination treatment with quetiapine in bipolar disorder patients. 29 Sep 2009
• Chitosan may decrease serum valproate and increase the risk of seizure reappearance. 22 Sep 2009
• Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. 16 Sep 2009
• [Correlation between renal tubular dysfunction and serum carnitine deficiency in cases with valproate therapy] 30 Aug 2009
• An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. 30 Aug 2009
• Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells. 30 Aug 2009
• MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. 30 Aug 2009
• New evidence that an epigenetic mechanism mediates testosterone-dependent brain masculinization. 30 Aug 2009
• Rational polytherapy. 30 Aug 2009
• Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy. 30 Aug 2009
• The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? 30 Aug 2009
• Pregnancy treatment guidelines: throwing the baby out with the bath water. 30 Aug 2009
• Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. 13 Aug 2009
• Cognitive function after fetal exposure to antiepileptic drugs. 4 Aug 2009
• Unilateral eyelid angiofibroma with complete blepharoptosis as the presenting sign of tuberous sclerosis. 30 Jul 2009
• Epilepsy: Should valproate be avoided during childbearing years? 30 Jul 2009
• Divalproex is not effective for children with bipolar disorder. 30 Jul 2009
• Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. 30 Jul 2009
• Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants. 30 Jul 2009
• Divalproex sodium in children with partial seizures: 12-month safety study. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Valproic Acid'

Definition: A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.

Chemical name: Pentanoic acid, 2-propyl-

Registry Number: 99-66-1

Descriptor UI: D014635

Alternative terms: Valproic Acid; Acid, Valproic; 2-Propylpentanoic Acid; 2 Propylpentanoic Acid; Divalproex; Convulsofin; Depakene; Depakine; Depakote; Vupral; Divalproex Sodium; Sodium, Divalproex; Semisodium Valproate; Valproate, Semisodium; Valproic Acid, Sodium Salt (2:1); Ergenyl; Magnesium Valproate; Valproate, Magnesium; Sodium Valproate; Valproate, Sodium; Valproate Sodium; Sodium, Valproate; Valproate; Calcium Valproate; Valproate, Calcium; Dipropyl Acetate; Acetate, Dipropyl;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antimanic Agents; Anticonvulsants; Enzyme Inhibitors; GABA Agents;

Tree Number: D02.241.081.944.509.900; D10.251.400.895.593.900;

Online Note: use VALPROIC ACID to search VALPROATE 1979-90 & DIPROPYL ACETATE 1975-90

History Note: 91; was VALPROATE 1979-90; was DIPROPYL ACETATE see under VALERATES 1975-78